Senores Pharmaceuticals Ltd
Incorporated in 2015, Senores Pharmaceuticals Ltd manufactures and develops affordable and high-quality complex generics certified by global food and drugs authorities[1]
- Market Cap ₹ 3,005 Cr.
- Current Price ₹ 652
- High / Low ₹ 719 / 435
- Stock P/E 51.5
- Book Value ₹ 171
- Dividend Yield 0.00 %
- ROCE 11.4 %
- ROE 11.8 %
- Face Value ₹ 10.0
Pros
- Debtor days have improved from 177 to 114 days.
Cons
- Stock is trading at 3.82 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Company might be capitalizing the interest cost
- Working capital days have increased from 21.7 days to 88.2 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE Healthcare BSE SmallCap BSE IPO BSE Allcap
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|
14 | 35 | 215 | 398 | |
12 | 23 | 173 | 309 | |
Operating Profit | 2 | 13 | 42 | 90 |
OPM % | 14% | 36% | 19% | 23% |
0 | 4 | 3 | 19 | |
Interest | 1 | 2 | 9 | 22 |
Depreciation | 1 | 2 | 10 | 17 |
Profit before tax | 1 | 12 | 25 | 71 |
Tax % | 13% | 32% | -31% | 17% |
1 | 8 | 33 | 58 | |
EPS in Rs | 1.01 | 8.59 | 10.31 | 12.72 |
Dividend Payout % | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 204% |
TTM: | 86% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 289% |
TTM: | 85% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
1 Year: | % |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 15% |
Last Year: | 12% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|
Equity Capital | 9 | 10 | 31 | 46 |
Reserves | 28 | 36 | 174 | 740 |
15 | 63 | 258 | 315 | |
8 | 23 | 160 | 126 | |
Total Liabilities | 59 | 131 | 622 | 1,227 |
7 | 27 | 235 | 429 | |
CWIP | 8 | 34 | 97 | 44 |
Investments | 15 | 16 | 0 | 0 |
29 | 53 | 289 | 754 | |
Total Assets | 59 | 131 | 622 | 1,227 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|
-10 | -1 | -20 | -46 | |
-24 | -48 | -54 | -429 | |
36 | 46 | 87 | 573 | |
Net Cash Flow | 2 | -3 | 13 | 98 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|
Debtor Days | 506 | 228 | 191 | 114 |
Inventory Days | 135 | 89 | 129 | 114 |
Days Payable | 324 | 388 | 389 | 136 |
Cash Conversion Cycle | 317 | -71 | -70 | 92 |
Working Capital Days | 359 | -7 | -16 | 88 |
ROCE % | 18% | 12% | 11% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
5 Aug - Senores Pharmaceuticals Limited has informed regarding schedule of Analyst/Investor meeting on August 12, 2025.
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
30 Jul - Senores Pharmaceuticals Limited has informed regarding transcript of Earnings Conference Call held on Thursday, July 24, 2025 for Q1FY26.
- Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 30 Jul
-
Disclosure Under Regulation 30 Of The SEBI (LODR) Regulations, 2015
28 Jul - USFDA inspection at US subsidiary completed with 3 minor procedural observations.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
24 Jul - Audio recording of Q1 FY2026 earnings call available on company website.
Concalls
-
Jul 2025Transcript PPT REC
-
May 2025Transcript PPT REC
-
May 2025TranscriptNotesPPT
-
Jan 2025Transcript PPT REC
Business Overview:[1]
SPL is global research driven pharmaceutical company which develops and manufactures
pharmaceutical products for the Regulated Markets of US, Canada and United Kingdom across various therapeutic areas and dosage forms, with a presence in Emerging Markets. Company develops and manufactures specialty, underpenetrated and complex pharmaceutical products. It also manufactures criticalcare injectables and APIs